Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for various diseases. With a market cap of $132.4 billion, Regeneron’s operations span various countries in North America, Europe, and Asia.

Shares of the biotech giant have substantially outperformed the broader market over the past year. Over the past 52 weeks, REGN stock notably gained 44.7%, outpacing the S&P 500 Index’s ($SPX) 27.7% returns. In 2024, REGN is up 36.8% compared to SPX’s nearly 18% gains on a YTD basis.